This study investigates the therapeutic impact of localized Dielectric Barrier Discharge (DBD) plasma therapy on chronic vaginitis, hypothesizing that DBD plasma significantly reduces clinical symptoms, wound size, and infection severity with minimal side effects and high patient satisfaction.

A randomized controlled trial was conducted involving 50 women diagnosed with chronic vaginitis who attended gynecology clinics affiliated with Shahid Beheshti University of Medical Sciences (Tehran, Iran) in 1403 (2024-2025). Participants were randomly assigned to either the intervention group (n=25), receiving weekly DBD plasma therapy for four weeks alongside standard medical care, or a control group (n=25) receiving only standard treatment. Clinical assessments were performed before and one month after intervention, including measurement of vaginal wound size, infection severity, treatment satisfaction, and side effects.

After intervention, the intervention group showed a significant reduction in mean wound size (14.80 ± 10.5 mm) compared to the control group (32.40 ± 7.23 mm; p < 0.001). The average wound size reduction post-treatment was also more substantial in the plasma group (−23.60 ± 9.95 mm) than in the control group (−10.5 ± 5.20 mm; p < 0.001). Furthermore, 68% of the plasma group demonstrated mild infection severity post-treatment versus only 8% in the control group (p < 0.001). Patient satisfaction was high: 56% reported being completely satisfied with DBD therapy, and only 8% reported minor, non-serious adverse effects.

The findings suggest that localized DBD plasma therapy can serve as an effective adjunctive treatment for chronic vaginitis by accelerating wound healing, reducing infection severity, and increasing patient satisfaction—all with minimal side effects. These benefits may offer a compelling alternative for cases resistant to standard medical therapies.

DBD plasma therapy significantly improves clinical outcomes in chronic vaginitis and is well tolerated. Its implementation in gynecological care could reduce the burden of chronic infections and enhance patient quality of life. Further large-scale clinical trials are recommended to validate these promising results.